KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation ExpenseEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Pacific Biosciences Of California (PACB) EBIAT (2016 - 2026)

Pacific Biosciences Of California has reported EBIAT over the past 16 years, most recently at -$40.4 million for Q4 2025.

  • For Q4 2025, EBIAT fell 1802.7% year-over-year to -$40.4 million; the TTM value through Dec 2025 reached -$546.4 million, down 76.34%, while the annual FY2025 figure was -$546.4 million, 76.34% down from the prior year.
  • EBIAT for Q4 2025 was -$40.4 million at Pacific Biosciences Of California, down from -$38.0 million in the prior quarter.
  • Over five years, EBIAT peaked at $2.4 million in Q4 2024 and troughed at -$426.1 million in Q1 2025.
  • A 5-year average of -$88.2 million and a median of -$71.4 million in 2022 define the central range for EBIAT.
  • Biggest five-year swings in EBIAT: plummeted 7028.29% in 2021 and later skyrocketed 102.89% in 2024.
  • Year by year, EBIAT stood at -$69.3 million in 2021, then decreased by 21.72% to -$84.4 million in 2022, then grew by 2.8% to -$82.0 million in 2023, then skyrocketed by 102.89% to $2.4 million in 2024, then plummeted by 1802.7% to -$40.4 million in 2025.
  • Business Quant data shows EBIAT for PACB at -$40.4 million in Q4 2025, -$38.0 million in Q3 2025, and -$41.9 million in Q2 2025.